Jennifer J. Cory, MA2, CRA
Director of Operations
Ms Cory has over 18 years of experience in management and operations in the academic setting and her career spans the pre-award, post-award, and compliance areas of research administration. At Stanford, she has extensive experience working with faculty in pediatrics, blood and marrow transplantation and stem cell biology and regenerative medicine. The most recent past position she held was as Director of Research Administration in the Department of Pediatrics, where she had oversight of research operations, facilities, financial management practices, research policies, and procedures. The Department's research portfolio spanned bench to bedside with sponsored research expenditures of ~$50M per year. Prior to coming to Stanford, she was a research manager in the medical school at the University of Oxford. She has participated in various University committees and focus groups that aim to improve the quality and management of research programs and is a nationally recognized speaker and faculty member for the National Council of University Research Administrators (NCURA), for which she travels to teach workshops in Departmental Research Administration and Contract Negotiation and Administration.
Annalisa Lattanzi, PhD
Discovery Stage Project Manager
Dr. Lattanzi has 14 years of carrier focusing on gene therapy, genome editing protocols and stem cell biology. At Stanford - CDCM she developed strong competences in project management of translational research projects, at the early stages of preclinical development and IND enabling activities. In particular, she is leading the management of therapeutic genome editing area, that uses the CRISPR/Cas9 technology as new tool with a wide range of applications from blood diseases to neuromuscular disorders and cancer. An extensive list of clinical trials is in the pipeline.
Prior to coming to Stanford, she conducted research activities at Genethon Institute in France, aimed at developing new therapeutics for life threatening monogenetic diseases such as Spinal Muscular Atrophy, Duchenne Muscular Dystrophy and Beta-Hemoglobinopathies. She received her PhD in Biotechnology and Molecular Biology from the Telethon Institute for Gene Therapy in Milan – Italy, where she studied neurogenesis and developed lentiviral-based therapeutic interventions into the central nervous system of disease animal models for Lysosomal Storage Disorders.
Angelica Martinez, MPA
Angelica Martinez, MPA currently serves as the Operations Manager for the Center for Definitive and Curative Medicine (CDCM) at Stanford University. Ms. Martinez has more than 15 years of relevant administration, operations, and research coordination experience in research-centered higher education institutions. She is responsible for day-to-day administrative and operational management of the CDCM, acting as key liaison to internal and external partners. Previously, she served as the Associate Director for Administration at the Health Equity Institute, San Francisco State University, where she was responsible for the overall budgetary, hiring, financial, and administrative processes. Ms. Martinez has also served as the Project Director for Gender-Economic Model (GEM) of HIV Risk in African-American and Latina Women at San Francisco State University and as Field Coordinator for the Intergenerational HIV Initiative for Latina Women (also “De Madre a Hija: Protegiendo Nuestra Salud”or “Mija”) at the Center for AIDS Prevention Studies, University of San Francisco, California.
Abinaya Nathan, PhD
Discovery Stage Project Manager
Abinaya Nathan is currently the Discovery Stage Project Manager for CDCM. She completed her PhD followed by a postdoctoral scientist position in an aging institute in Germany. She worked at Stanford as a Research Scientist working on pulmonary arterial hypertension and its impact on cardiovascular disease. During that time, she was a key player in the academic setting by performing and planning experiments of in vivo and in vitro biochemical/ cellular assays leading to a number of scientific publications. Alongside, she was also responsible in managing the lab in both, lab supply replenishment as well as supervision of high school and undergraduate students. Her current role is to plan, coordinate and manage investigator-initiated translational research projects of cell and gene therapies from its development to filing and submission of the IND.
Rhonda Perriman, PhD
Grants Manager and Scientific Editor
Rhonda Perriman is the Grants Manager and Scientific Editor for the CDCM. She completed her PhD. at Australian National University and her postdoctoral training as an American Cancer Society fellow at the University of California, Santa Cruz (UCSC). Following this training, she worked as a Senior Research Scientist at UCSC studying structure-function relationships within the multi-subunit RNA-protein enzyme (spliceosome) responsible for pre-mRNA splicing in eukaryotes. Her research provided substantial insights into the mechanistic details of novel spliceosomal RNA rearrangements that are required for accurate pre-mRNA splicing, and identified key protein co-factors that aid these. She is proficient in genetics, genomics, biochemistry, and molecular biology. Currently she leads the preparation of scientific proposals, grant applications and original manuscripts being submitted by faculty in the CDCM and Stem Cell Transplant and Regenerative Medicine. She also assists in the preparation of pre- and IND submissions to the FDA for approval of Clinical Trials.
Director of Business Development
Devan Shah has passion for bio-innovation and a background in biotech operations, business development, and investing. He has worked with computational drug discovery companies in executing successful VC-led financings and was most recently VP of Business Operations at a computational pathology company named 3Scan. Previously, he spent time at New Leaf Venture Partners, a healthcare VC firm, where he invested in and analyzed investments in biopharma, medical device, healthcare IT, and diagnostics companies at all stages of the capital cycle (both private and public companies). Devan started his career in the Global Healthcare Group at Citigroup’s Investment Banking Division in New York City.